Article
The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders.
Drug metabolism and personalized therapy - 1 Jun 2023
Kibitov Andrey Alexandrovitch, Kiryanova Elena Mikhaylovna, Salnikova Ludmila Ivanovna, Bure Irina Vladimirovna, Shmukler Alexander Borisovitch, Kibitov Alexander Olegovitch
Abstract excerpt
OBJECTIVES: Extrapyramidal symptoms (EPS) are one of the most prominent side effects of haloperidol. Variability of EPS severity may be associated with the genetic factors, affecting both haloperidol pharmacokinetics (e.g., CYP2D6) and pharmacodynamics (e.g., DRD2, ANKK1). We conducted a 3-week prospective study to investigate the associations of ANKK1/DRD2 TaqIA (rs1800497), DRD2 -141C Ins/Del (rs1799732)...
Read the complete abstract on PubMed